by Keishi Foecke | Dec 19, 2025 | Blog Post
This year, life sciences mergers and acquisitions (M&A) played a crucial role in driving innovation and supporting America’s global leadership in the life sciences. As the leading advocacy coalition on life sciences M&A, PULSE educated stakeholders and...
by Keishi Foecke | Dec 10, 2025 | Blog Post
Following a challenging funding and policy environment, new data shows an uptick in biopharmaceutical mergers and acquisitions (M&A). This is an encouraging sign of a healthy biopharmaceutical innovation ecosystem. As experts observe continued funding pressures on...
by Keishi Foecke | Nov 20, 2025 | Innovations Advanced by M&A
This blog is another installment in a series, Innovations Advanced by M&A, that underscores the unique role of mergers and acquisitions in promoting a competitive and innovative life sciences ecosystem for patients. You can find previous blogs in this series here....
by Keishi Foecke | Nov 6, 2025 | Blog Post
Despite decades of biomedical breakthroughs, 95% of the 7,000 identified rare diseases still lack an approved treatment or cure. While these diseases may be individually rare, they collectively impact 1 in 10 Americans. To address these unmet medical needs requires...
by Keishi Foecke | Oct 22, 2025 | Blog Post
Recent commentary from senior Federal Trade Commission (FTC) and Department of Justice (DOJ) officials signaled a continued commitment to activist antitrust enforcement – compounding the uncertainty for thousands of small and early-state life science companies that...
by Keishi Foecke | Oct 9, 2025 | Blog Post
In a recent study published in Concurrences Law & Economics, Cornerstone Research experts found a significant association between biopharmaceutical mergers and acquisitions (M&A) and the likelihood of new and novel therapies coming to market. After analyzing...
